Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tuya and LifeStance and Encourages Investors to Contact the Firm


NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Tuya, Inc. (NYSE: TUYA) and LifeStance Health Group, Inc. (NASDAQ: LFST). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Tuya, Inc. (NYSE: TUYA)

Class Period: Pursuant to the Company’s March 18, 2021 IPO

Lead Plaintiff Deadline: October 11, 2022

According to the Complaint, the Company made false and misleading statements to the market. Tuya’s China-based customers engaged in a scheme to manipulate reviews and product offerings on Amazon, in violation of the -commerce platform’s terms of use. A consumer investigation that occurred prior to the IPO uncovered organized fake review scams perpetrated by the Company’s clients which included 200,000 fake Amazon accounts that posted 13 million fake reviews. The Company was likely to suffer significant business challenges if its base of clients were barred from selling on the Amazon platform. Based on these facts, the Company’s public statements were false and materially misleading throughout the IPO period. When the market learned the truth about Tuya, investors suffered damages.

For more information on the Tuya class action go to: https://bespc.com/cases/TUYA

LifeStance Health Group, Inc. (NASDAQ: LFST)

Class Period: Pursuant to the Company’s June 11, 2021 IPO

Lead Plaintiff Deadline: October 11, 2022

On or about June 11, 2021, LifeStance conducted its IPO, issuing 46 million shares at $18 per share.

On August 11, 2021, LifeStance announced its financial results for second quarter 2021, which ended just days after the IPO. The Company reported a net loss of $70 million and also disclosed that its operating expenses had more than tripled during the second quarter. LifeStance stated that it had experienced a significant, negative “recent change in clinician retention levels.”

On this news, the Company’s stock price fell $10.16, or 46%, to close at $11.71 per share on August 12, 2021, thereby injuring investors.

Then, on November 8, 2021, LifeStance released its third quarter 2021 financial results, disclosing that “[c]linician retention [had] stabilized to approximately 80% annualized in the third quarter,” and that the Company was having to increase spending on “enhanced clinician engagement and continued support for workplace and work-life flexibility.”

On this news, the Company’s stock price fell $3.10, or 24%, to close at $9.73 per share on November 9, 2021, thereby injuring investors further.

Then, on March 10, 2022, LifeStance reported its fiscal 2021 results, stating that a recent study had shown that three quarters of mental health patients prefer in-person services and that through 2021, telehealth services trended downwards. Additionally, the Company stated that it would be reducing the number of brick and mortar facilities that it would be building in the immediate future in order to increase its profitability.

At the time the complaint was filed, LifeStance’s common stock has traded as much as 73% below than the IPO price.

The complaint filed in this class action alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the number of virtual visits clients were undertaking utilizing LifeStance was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining the Company’s out-patient/virtual revenue growth; (2) that the percentage of in-person visits clients were undertaking utilizing LifeStance was increasing as the COVID-19 lockdowns were being lifted, thereby causing the Company’s operating expenses to increase substantially; (3) that LifeStance had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the Registration Statement and the Company had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

For more information on the LifeStance class action go to: https://bespc.com/cases/LFST

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com